Business Context and Reporting Period
Company: Proteon Therapeutics, Inc. (Note: Input metadata referenced "Protara," but the filing identifies the registrant as Proteon Therapeutics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2018
Reporting Period: Second Quarter ended June 30, 2018
Status: Emerging Growth Company
Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the attached Exhibit 99.1 (Press Release), which is incorporated by reference but not included in the provided source text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. It directs readers to the attached press release for the announcement of second-quarter financial results.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on August 7, 2018, announcing its financial results for the quarter ended June 30, 2018.
Legal Disclaimer: The information under Item 2.02 and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that Section, except as expressly set forth by specific reference in other filings.
Key Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release, as they are absent from the 8-K body text.
- Confirm the company's status as an Emerging Growth Company and any associated election regarding extended transition periods for accounting standards.
- Note that the financial data in this report is not subject to Section 18 liabilities of the Exchange Act unless specifically referenced in other filings.